摘要
目的探讨高危型人乳头瘤病毒(HR-HPV)检测在宫颈癌及其癌前病变随访中的临床意义。方法采用HPV-DNA检测(HC-2)、薄层液基细胞学检查(LCT)对术后组织病理学确诊为宫颈癌及其癌前病变的174例病人进行追踪随访。结果经规范治疗后随访过程中,术后1、3、10与22月HR-HPV-DNA检测预测病变残留或复发的阳性预测值分别为23.9%30.8%、55.2%与45.7%,阴性预测值均为100%。宫颈锥切组1、3、10及22月HPV阴性率分别为65.0%、68.9%、87.2%与86.7%;全子宫切除组1、3、10及22月HPV阴性率分别为63.2%、70.6%、75.0%与79.4%;广泛子宫切除组1、3、10及22月HPV阴性率分别为53.0%、71.0%、80.0%与67.0%。结论 HR-HPV-DNA检测在宫颈癌及宫颈上皮内瘤变治疗后随访中起重要作用。针对不同级别病变采用的手术方式均可有效清除HPV感染,但其转阴需要一定时间。治疗后HR-HPV仍阳性者应及时进行干预,以减少病变复发。
Objective To approach the clinical significance of the high-risk human papillomavirus （HR-HPV） in the fol- low-up of cervieal cancer and precancerous lesions. Methods Follow-up using HPV-DNA testing （HC-2） and thin layer liquid- based cytology （LCT） on 174 patients, whose postoperative histological diagnosis was cervical cancer or precancerous lesion. Re- sults With standard treatment, After 1 month,3 months, 10 months,22 months of follow-up, HR-HPV-DNA test results can pre- dict residual or recurrent lesions, and it＇s positive predictive value was 23. 9%, 30. 8%, 55. 2%, 45.7%, respeetively~ the nega- tive predictive values were all 100 %. After 1 month,3 months, 10 months,22 months of follow-up, H PV-negative rates of the pa- tients who had cervical eonization were 65.0% ,68.9% ,87.2% ,86.7% ,respeetively;the rates of the patients who had hysterecto- my were 63.2%,70.6% ,75.0%,79.4% sand the rates of the patiens who had radical hysterectomy were 53.0% ,71.0%,80.0%, 67.0%. Conclusion HR-HPV-DNA detection plays an important role in cervical cancer and cervical intraepithelial neoplasia＇s follow-up. The surgical modes for different levels of disease can removal HPV infection effectively. However,it perhaps takes some time. After treatment,the HR-HPV-positive patients should been intervened in oder to reduse the residue or recurrence.
出处
《青岛大学医学院学报》
CAS
2010年第6期487-489,共3页
Acta Academiae Medicinae Qingdao Universitatis
关键词
人乳头瘤病毒
宫颈肿瘤
随访研究
human papillomavirus
uterine cervical neoplasms
follow-up studies
